In this paper, we developed BreastScreening-AI within two scenarios for the classification of multimodal beast images: (1) Clinician-Only; and (2) Clinician-AI. The novelty relies on the introduction of a deep learning method into a real clinical workflow for medical imaging diagnosis. We attempt to address three high-level goals in the two above scenarios. Concretely, how clinicians: i) accept and interact with these systems, revealing whether are explanations and functionalities required; ii) are receptive to the introduction of AI-assisted systems, by providing benefits from mitigating the clinical error; and iii) are affected by the AI assistance. We conduct an extensive evaluation embracing the following experimental stages: (a) patient selection with different severities, (b) qualitative and quantitative analysis for the chosen patients under the two different scenarios. We address the high-level goals through a real-world case study of 45 clinicians from nine institutions. We compare the diagnostic and observe the superiority of the Clinician-AI scenario, as we obtained a decrease of 27% for False-Positives and 4% for False-Negatives. Through an extensive experimental study, we conclude that the proposed design techniques positively impact the expectations and perceptive satisfaction of 91% clinicians, while decreasing the time-to-diagnose by 3 min per patient.

Breast cancer is a highly heterogeneous disease with diverse molecular profiles. Recent AI models have attempted to predict PAM50 subtype, as a standard for classifying breast cancer into intrinsic subtypes, from histopathology images, most depend on random patch sampling that introduces redundancy and restricts the model performance.In this study, we introduce a novel optimization-driven deep learning framework that aims to reduce reliance on costly molecular assays by directly predicting PAM50 subtypes from H&E-stained whole-slide images (WSIs). Our method jointly optimizes patch informativeness, spatial diversity, uncertainty, and patch count by combining the non-dominated sorting genetic algorithm II (NSGA-II) with Monte Carlo dropout-based uncertainty estimation. The proposed method can identify a small but highly informative patch subset for classification. We used a ResNet18 backbone for feature extraction and a fully connected head for classification. For evaluation, we used the internal TCGA-BRCA dataset as the training cohort and the external CPTAC-BRCA dataset as the test cohort. On the internal dataset, an F1-score of 0.8964 and an AUC of 0.9865 using 627 WSIs from the TCGA-BRCA cohort were achieved. The performance of the proposed approach on the external validation dataset showed an F1-score of 0.7995 and an AUC of 0.9523.These findings indicate that the proposed optimization-guided, uncertainty-aware patch selection can achieve high performance and improve the computational efficiency of histopathology-based PAM50 classification compared to existing methods, suggesting a scalable imaging-based replacement that has the potential to support clinical decision-making.